Journal Article Ppublish 1 citation
PubMed: 40673101 DOI: 10.21037/tlcr-2024-1034
Response of non-small cell lung cancer harboring different epidermal growth factor receptor mutations to ablative radiotherapy.
Transl Lung Cancer Res 14(6):2062-2073
Authors: Areej Al Rabea, Ian J Gerard, Paul Daniel, Sophie Camilleri-Broët, Ayman Oweida, Siham Sabri, Bassam Abdulkarim
Affiliations
- Division of Experimental Surgery, McGill University, Montreal, QC, Canada.
- Department of Oncology, McGill University, Research Institute of the McGill University Health Centre (Research Institute-MUHC), Montreal, Canada.
- Department of Pathology, McGill University, Montreal, QC, Canada.
- Department of Nuclear Medicine and Radiobiology, University of Sherbrooke, Sherbrooke, QC, Canada.
- Research Institute, Cancer Research Program, McGill University Health Centre, Montreal, Quebec, Canada.
- Department of Oncology, Division of Radiation Oncology, Cedars Cancer Centre, McGill University McGill University Health Centre, Montreal, Quebec, Canada.
Abstract
Background
Stereotactic ablative radiation therapy (SABR) provides an alternative treatment for patients with inoperable early-stage lung cancer (ES-LC). The epidermal growth factor receptor (EGFR) plays an important role in tumor progression and treatment resistance in non-small cell lung cancer (NSCLC). EGFR-targeted therapies in combination with radiotherapy (RT) have not been successful at enhancing RT's response or improving tumor control. The response of NSCLCs carrying EGFR mutations to SABR has not been well investigated, although worse overall survival is seen among patients with L858R-EGFR mutations. We aim to evaluate the effect of different EGFR-mutant lung cancers to SABR in vitro and in vivo and provide a deeper understanding of the mechanisms of response and resistance to SABR.
Methods
A549 cells were stably transfected with either wild-type-EGFR (WT), deleted-EGFR (DEL), or L858R-EGFR (L858R) constructs to generate isogenic cell lines. In vitro assessment included colony formation, cell viability, and proliferation assays. Tumor formation was assessed by subcutaneous injection of pre-irradiated cells in yellow fluorescent protein (YFP)/severe combined immunodeficiency (SCID) mice. All mice were sourced from the Animal Resource Division at the McGill University Healthcare Centre. Response to SABR was evaluated in mice injected subcutaneously with isogenic cells and followed with sham or 34 Gy treatment. Tumors collected from both groups were evaluated for SABR effect histologically.
Results
EGFR-mutant cell lines displayed a similar in vitro response to SABR: reduced colony formation, cell viability, and cell cycle arrest in G2. Pre-irradiated WT-EGFR and L858R-EGFR NSCLC cell lines maintained their ability to initiate tumor growth in vivo, whilst pre-irradiated DEL-EGFR cells were unable to form tumors upon injection. Subcutaneous DEL-EGFR xenograft tumors had a significant decrease in tumor volume post-SABR treatment compared to WT and L858R-EGFR xenografts. Histological assessment demonstrated less necrosis and a decrease (P=0.049) of apoptotic cells in DEL-EGFR-treated tumors compared to L858R-EGFR.
Conclusions
Novel demonstration of DEL-EGFR mutation imparting better response to SABR compared to WT-EGFR or L858R-EGFR mutations, consistent with findings from The Cancer Genome Atlas (TCGA), suggesting L858R-EGFR mutations are associated with worse overall survival. Radiation dose fractionation should be investigated further to establish an optimal SABR regimen in the context of LCs and possible overall survival with EGFR mutations.
MeSH
Radiotherapy, Injections, Cells, Epidermal Growth Factor, Lung, Growth, Cell Survival, Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Cell Line, Receptors, Growth Factor, Small Cell Lung Carcinoma, Therapeutics, Injections, Subcutaneous, Mutation, Dose Fractionation, Radiation, Heterografts, Egfr Mutation